Kamada Ltd. Reports New Data From an Extension Study of Its Phase I/II Trial With Glassia in Pediatric Patients With Type 1 Diabetes
Published: Oct 31, 2013
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company’s ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).
Help employers find you! Check out all the jobs and post your resume.